Shares of DRI Healthcare Trust (TSE:DHT.UN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is C$18.00.
Several research analysts recently issued reports on DHT.UN shares. Scotiabank upped their target price on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Raymond James decreased their price objective on shares of DRI Healthcare Trust from C$23.00 to C$22.00 in a research report on Wednesday, November 13th.
Get Our Latest Stock Analysis on DHT.UN
DRI Healthcare Trust Trading Up 0.6 %
DRI Healthcare Trust Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, October 18th. Investors of record on Friday, October 18th were issued a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 3.91%. The ex-dividend date of this dividend was Friday, September 27th. DRI Healthcare Trust’s dividend payout ratio (DPR) is -920.00%.
DRI Healthcare Trust Company Profile
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
Further Reading
- Five stocks we like better than DRI Healthcare Trust
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is the S&P 500 and How It is Distinct from Other Indexes
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for DRI Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DRI Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.